SEC Filing Analysis: UNITED THERAPEUTICS Corp

Executive Summary

• Trading Significance: Low
• Key Takeaway: The Founder, Chairperson, and CEO of United Therapeutics filed a Form 144 notice for a proposed sale of $1.8 million in common stock, executed under a pre-arranged 10b5-1 trading plan.
• Market Impact: Negligible, due to the transaction's small size relative to the company's market capitalization and its pre-planned nature.

Company Information

Field	Value
Company	UNITED THERAPEUTICS Corp
Ticker Symbol	Not provided in filing
CIK	0001082554
Industry	PHARMACEUTICAL PREPARATIONS

Insider Information

Field	Value
Name	ROTHBLATT MARTINE A
CIK	0001106578
Title/Position	FOUNDER, CHAIRPERSON, AND CHIEF EXECUTIVE OFFICER
Relationship	Officer, Director

Transaction Details

Field	Value
Form Type	144
Transaction Date	2025-11-07 (Approximate Sale Date)
Transaction Code	Not Applicable
Security Type	COMMON
Shares Involved	4,000
Price Per Share	~$448.25 (calculated)
Total Value	$1,793,008.00
Shares Owned After	Not Stated
Ownership Type	Not Stated

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$1,793,008
% of Market Cap	0.009%
Shares Transacted	4,000
% of Shares Outstanding	0.009%
Post-Transaction Ownership	Not Stated
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: For a large-cap company with a market capitalization of $19.55 billion, this $1.8 million transaction is financially immaterial.
• Transaction Significance: The sale represents less than 0.01% of both the market cap and the total shares outstanding, falling well below any threshold for significance.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: The transaction is a notice of a proposed sale under a 10b5-1 plan, which removes its value as a timely signal of insider sentiment. The size is too small to affect the market.

Volume & Sentiment

• Expected Volume Impact: None. The transaction size is minimal compared to daily trading volume.
• Sentiment Indicator: Neutral. Pre-planned sales by executives for liquidity or diversification purposes are routine and do not typically influence market sentiment.

Additional Context

Transaction Notes

• Special Circumstances: The filing indicates the sale is pursuant to a trading plan adopted on May 2, 2025. The document also details a consistent pattern of similar-sized sales by the same insider over the past three months, reinforcing the planned nature of these dispositions.